Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 1, 2012, Pages 69-77

  Icardi, Giancarlo ^a   Orsi, Andrea ^a   Ceravolo, Antonella ^a   Ansaldi, Filippo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Acceptability; Immunogenicity; Influenza vaccine; Intradermal; Micro injection system; Safety; Tolerability

Indexed keywords

INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MIFAMURTIDE; VIROSOME;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; DENDRITIC CELL; DRUG DOSE COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; GERIATRIC PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE ECCHYMOSIS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MYALGIA; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING;

EID: 84857196747     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/8.1.18419     Document Type: Review

References (89)

1. Nokleby H, Nicoll A. Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11. Euro Surveill 2010; 15:19525.
2. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62; PMID: 20689501
3. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; http://dx.doi.org/10.1016/j.vaccine.2005.08.105
4. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16:357-64; PMID:12857772; http://dx.doi.org/10.1128/CMR.16. 3.357-364.2003
5. Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011; 186:6044-55; PMID:21498665; http://dx.doi.org/10.4049/jimmunol.1004095
6. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2:659-66; PMID:12409046; http:// dx.doi.org/10.1016/S1473-3099(02)00437-1
7. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, et al. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009; 27:5043-53; PMID:19559118; http:// dx.doi.org/10.1016/j. vaccine.2009.06.032
8. Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011; 28: 93-106; PMID:21275435; http://dx.doi.org/10.2165/11586770-000000000-00000
9. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/ 1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61:94-9; PMID:10745239; http://dx.doi.org/10.1002/(SICI)1096-9071(200005) 61:1<94::AID-JMV15>3.0. CO;2-C
10. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/ 1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/ 2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063-5; PMID:16464520; http://dx. doi.org/10.1016/j. vaccine.2006.01.015
11. Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24:5966-9; PMID: 16777274; http://dx.doi.org/ 10.1016/j.vaccine.2006.05.009
12. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25:6852-62; PMID: 17719149; http://dx.doi.org/10.1016/j. vaccine.2007.07.027
13. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination- inhibiting antibody activity against A (H3N2) drifted influenza viruses. Vaccine 2008; 26: 1525-9; PMID:18294741; http://dx.doi.org/ 10.1016/j.vaccine.2008.01.019
14. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28:4123-9; PMID:20433807; http://dx.doi.org/10.1016/j.vaccine.2010.04.030
15. Müller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based crosssectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 2007; 35:308-19; PMID:17885730; http://dx.doi.org/10.1007/s15010-007-6218-5
16. Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8:272; PMID: 18673545; http://dx.doi.org/10.1186/1471-2458-8-272
17. Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in hospitals-a review of studies on attitudes and predictors. Vaccine 2009; 27:3935-44; PMID:19467744; http://dx.doi.org/10.1016/ j.vaccine.2009.03.056
18. Keeton VF, Chen AK. Immunization updates and challenges. Curr Opin Pediatr 2010; 22:234-40; PMID:20125025; http://dx.doi.org/10.1097/MOP. 0b013e328337685b
19. Chua JV, Chen WH. Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Crit Care 2010; 14:218; PMID:20497595; http://dx.doi.org/10.1186/cc8891
20. Payler DK, Skirrow MB. Letter: Intradermal influenza vaccination. BMJ 1974; 2:727; PMID:4852830; http://dx.doi.org/10.1136/bmj.2.5921.727-a
21. Centers for Disease Control and Prevention (CDC). State-specific influenza vaccination coverage among adults aged > or =18 years-United States, 2003-04 and 2005-06 influenza seasons. MMWR Morb Mortal Wkly Rep 2007; 56:953-9; PMID:17882124
22. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-42; PMID:18023942; http://dx.doi.org/10.1016/j.vaccine.2007.10.020
23. Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, Nicolas JF, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007; 25:6423-30; PMID:17640778; http://dx.doi.org/10. 1016/j.vaccine.2007.05.046
24. Esposito S, Daleno C, Picciolli I, Tagliaferri L, Scala A, Prunotto G, et al. Immunogenicity and safety of intradermal influenza vaccine in children. Vaccine 2011; 29:7606-1.
25. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993; 92:2587-96; PMID:8254016; http://dx.doi.org/10.1172/JCI116873
26. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol 1993; 151:6535-45; PMID:7504023
27. Spellberg B. The cutaneous citadel: a holistic view of skin and immunity. Life Sci 2000; 67:477-502; PMID: 10993114; http://dx.doi.org/10.1016/S0024- 3205(00)00653-6
28. Flacher V, Bouschbacher M, Verronèse E, Massacrier C, Sisirak V, Berthier-Vergnes O, et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol 2006; 177:7959-67; PMID:17114468
29. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14; PMID: 18844594; http://dx.doi.org/10.1586/14760584.7.8. 1201
30. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine 2008; 26:3197-208; PMID:18486285; http://dx.doi.org/10.1016/j.vaccine.2008.03.095
31. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006; 24:191-201; PMID:16473831; http://dx.doi.org/10.1016/j.immuni.2006.01.005
32. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, Zhan Y, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006; 25:153-62; PMID:16860764; http://dx.doi.org/10.1016/j.immuni.2006.04.017
33. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000; 78:693-8; PMID:10859864
34. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992; 14:697-707; PMID: 1532914; http://dx.doi.org/10.1093/clinids/14.3.697
35. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 1985; 254:3203-6; PMID: 2933535; http://dx.doi.org/10.1001/jama.254.22.3203
36. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009; 16:1709-19; PMID:19793898; http:// dx.doi.org/10.1128/CVI.00290-09
37. Mantoux C. L'intradermo-réaction a la tuberculine et son interprétation clinique. Presse Med 1910; 18:10-3.
38. Tuft L. Active immunization against typhoid fever with particular reference to intradermal method. J Lab Clin Med 1931; 16:552.
39. Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. Bull World Health Organ 1967; 36:375-84; PMID:5299670
40. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997; 25:323-38; PMID:9325001; http://dx.doi.org/10.1006/biol.1997.0103
41. McBean AM, Agle AN, Compaore P, Foster SO, McCormack WM. Comparison of intradermal and subcutaneous routes of cholera vaccine administration. Lancet 1972; 1:527-9; PMID:4110029; http://dx.doi.org/10.1016/S0140-6736(72)90187-0
42. Nicholson KG, Prestage H, Cole PJ, Turner GS, Bauer SP. Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine. Lancet 1981; 2:915-8; PMID:6117693; http://dx.doi.org/10.1016/S0140-6736(81)91402-1
43. Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for postexposure rabies prophylaxis. Lancet 1985; 1:1059-62; PMID:2860284; http://dx.doi.org/10.1016/S0140-6736 (85)92367-0
44. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983; 2:1454-6. (Pubitemid 14203373)
45. Goldwater PN, Woodfield DG, Ramirez AM, Anzimlt IS. Intradermal, low dose, short course hepatitis B vaccination. N Z Med J 1986; 99:703-5; PMID: 2950344
46. Halsey NA, Reppert EJ, Margolis HS, Francis DP, Fields HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 1986; 4:228-32; PMID: 3541426; http://dx.doi.org/10.1016/0264-410X(86) 90134-9
47. Clarke JA, Hollinger FB, Lewis E, Russell LA, Miller CH, Huntley A, et al. Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites. JAMA 1989; 262:2567-71; PMID:2530364; http://dx.doi.org/10.1001/jama.262. 18.2567
48. Connolly JH, Dick GW. Antibody response following intradermal or oral administration of formalinised poliomyelitis. Lancet 1958; 2:333-6; PMID:13576796; http://dx.doi.org/10.1016/S0140-6736(58)90256-3
49. Samuel BU, Cherian T, Sridharan G, Mukundan P, John TJ. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet 1991; 338: 343-4; PMID:1677699; http://dx.doi.org/10.1016/0140-6736(91)90480-D
50. Samuel BU, Cherian T, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine 1992; 10:135; PMID:1311491; http://dx.doi.org/10.1016/0264-410X(92)90039-M
51. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998; 16:928-31; PMID: 9682339; http://dx.doi.org/10.1016/S0264-410X(97) 00293-4
52. Weller TH, Cheever FS, Enders JF. Immunologic reactions following the intradermal inoculation of influenza A and B vaccine. Proc Soc Exp Biol Med 1948; 67:96-101; PMID:18902305
53. Boger WP, Liu OC. Subcutaneous and intradermal vaccination with Asian influenza vaccine. J Am Med Assoc 1957; 165:1687-9; PMID:13475081
54. McCarroll JR, Kilbourne ED. Immunization with Asian-strain influenza vaccine: equivalence of the subcutaneous and intradermal routes. N Engl J Med 1958; 259:618-21; PMID:13590412; http://dx.doi. org/10.1056/NEJM195809252591304
55. Klein M, Huang N. The response of infants and children to Asian influenza vaccine administered by intradermal and subcutaneous routes. J Pediatr 1961; 58:312-4; PMID:13756667; http://dx.doi.org/10. 1016/S0022-3476(61)80260-6
56. McElroy JT, Szwed JJ. Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine. N Engl J Med 1969; 281:1076; PMID:5343531; http://dx. doi.org/10.1056/NEJM196911062811921
57. Phillips CA, Forsyth BR, Christmas WA, Gump DW, Whorton EB, Rogers I, et al. Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization. J Infect Dis 1970; 122:26-32; PMID:5433710; http://dx.doi.org/10. 1093/infdis/122.1-2.26
58. Foy HM, Sealey L, Cooney MK, Bor E. Efficacy of intradermally administered A2 Hong Kong vaccine. JAMA 1970; 213:130; PMID:5467968; http://dx.doi. org/10.1001/jama.213.1.130
59. Marks MI, Eller JJ. Intradermal influenza immunization. Experience with Hong Kong vaccine. Am Rev Respir Dis 1971; 103:579-81; PMID:5550353
60. Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977; 136(Suppl):S466-71; PMID:606768; http://dx. doi.org/10.1093/infdis/136. Supplement-3.S466
61. Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann Allergy 1977; 39:110-2; PMID:889154
62. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/ 75: report of a study and review of the literature. Am J Public Health 1979; 69:1247-51; PMID:507256; http://dx.doi.org/10.2105/AJPH.69.12.1247
63. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979; 140:234-8; PMID:479641; http://dx. doi.org/10.1093/infdis/140.2.234
64. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-9; PMID:19022318; http://dx.doi.org/ 10.1016/j.vaccine.2008.10.077
65. Hickling JK, Jones KR. Intradermal delivery of vaccines: a review of the literature and potential for development for use in low- and middle-income countries. Seattle: Program for Appropriate Technology in Health (PATH); 2009. Available at: http:// www.path.org/files/TS-opt-idd-review.pdf. Accessed July 20, 2011.
66. Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011; 89:221-6; PMID:21379418; http://dx.doi.org/10. 2471/BLT.10.079426
67. Song JM, Kim YC, Barlow PG, Hossain MJ, Park KM, Donis RO, et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010; 88:244-7; PMID:20851715; http://dx.doi. org/10.1016/j.antiviral.2010.09.001
68. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915-20; PMID:20639891; http://dx.doi.org/ 10.1038/nm.2182
69. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010; 201: 190-8; PMID:20017632; http://dx.doi.org/10.1086/ 649228
70. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009; 27:6932-8; PMID:19761836; http://dx.doi.org/10. 1016/j.vaccine.2009.08.108
71. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 2011; 18:647-54; PMID: 21288996; http://dx.doi.org/10.1128/CVI.00435-10
72. Quan FS, Kim YC, Compans RW, Prausnitz MR, Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using micro-needles. J Control Release 2010; 147:326-32; PMID: 20692307; http://dx.doi.org/10.1016/j.jconrel.2010. 07.125
73. Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine 2003; 21:1786-8; PMID: 12686095; http://dx.doi.org/10.1016/S0264-410X(03) 00073-2
74. Committee for Human Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. 1997. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/ 2009/09/WC500003945.pdf. Accessed July 20, 2011.
75. Klein M, Huang N. The response of infants and children to Asian influenza vaccine administered by intradermal and subcutaneous routes. J Pediatr 1961; 58:312-4; PMID:13756667; http://dx.doi.org/10. 1016/S0022-3476(61)80260-6
76. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007; 119:1076-82; PMID:17545373; http://dx.doi.org/10.1542/peds. 2006-3176
77. Sugimura T, Ito Y, Tananari Y, Ozaki Y, Maeno Y, Yamaoka T, et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccina tion. Vaccine 2008; 26:2700-5; PMID:18436353; http://dx.doi.org/10.1016/j.vaccine.2008.03.016
78. Chiu SS, Chan KH, Tu W, Lau YL, Peiris JS. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009; 27:4834-9; PMID:19523908; http://dx. doi.org/10.1016/j.vaccine.2009.05.066
79. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-9; PMID:18930093; http://dx. doi.org/10.1016/j.vaccine.2008.09.078
80. Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; PMID: 19341446; http://dx.doi.org/10.1186/1741-7015- 7-13
81. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346-54; PMID: 20372053; http://dx.doi.org/10.4161/hv. 6.4.10961
82. Frenck RW, Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(®)) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http://dx.doi.org/10.1016/j.vaccine.2011.06.010
83. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94; PMID:15525713; http://dx. doi.org/10.1056/NEJMoa043555
84. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650-8; PMID:18652550; http://dx.doi.org/10.1086/ 590434
85. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, et al. Intradermal influenza vaccine for older adults: a randomized controlled multi-center phase III study. Vaccine 2009; 27:7304-12; PMID:19849996; http://dx.doi.org/10.1016/j.vaccine.2009.10.033
86. Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10:134; PMID:20504306; http://dx.doi.org/10.1186/ 1471-2334-10-134
87. Morelon E, Pouteil Noble C, Daoud S, Cahen R, Goujon-Henry C, Weber F, et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010; 28:6885-90; PMID:20709000; http://dx.doi.org/10.1016/ j.vaccine.2010.08.015
88. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin 2010; 6:336-45; PMID:20372083; http://dx.doi.org/10.4161/hv.6.4.10753
89. Arnou R, Frank M, Hagel T, Prébet A. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv Ther 2011; 28:555-65; PMID:21626269; http://dx.doi.org/10.1007/s12325-011-0035-z